{"id":23749,"date":"2022-12-08T16:25:00","date_gmt":"2022-12-08T08:25:00","guid":{"rendered":"https:\/\/flcube.com\/?p=23749"},"modified":"2025-01-29T16:30:09","modified_gmt":"2025-01-29T08:30:09","slug":"yantai-dongcheng-pharma-acquires-rights-to-18f-apn-1607-from-aprinoia-therapeutics","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=23749","title":{"rendered":"Yantai Dongcheng Pharma Acquires Rights to 18F-APN-1607 from Aprinoia Therapeutics"},"content":{"rendered":"\n

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675<\/a>) announced the plan to acquire the clinical trial approval and research and development (R&D) materials of 18F-APN-1607, a Tau protein positron photography tracer used for PET imaging diagnosis, from Japan\u2019s Aprinoia Therapeutics Inc. and Aprinoia Therapeutics Suzhou, along with exclusive clinical development, manufacturing, and marketing rights in mainland China.<\/p>\n\n\n\n

Transaction Details<\/strong>
Dongcheng Pharma will pay Aprinoia Japan USD 8 million in cash and Aprinoia Suzhou RMB 14 million (USD 2 million) in upfront payments, and is committed to USD 2 million in milestone payments and sales commission.<\/p>\n\n\n\n

18F-APN-1607: Mechanism and Potential Applications<\/strong>
18F-APN-1607, a preparation that can specifically combine with Tau protein accumulated in the brain to diagnose Alzheimer’s disease (AD), can also potentially be used to detect non-AD Tau-related diseases, such as progressive supranuclear palsy (PSP), cortical basal ganglia degeneration (CBD), and others.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) announced the plan to acquire the…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[3371,62,158,20,937],"class_list":["post-23749","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-aprinoia-therapeutics","tag-clinical-trial-approval-initiation","tag-dongcheng-pharmaceutical","tag-finance","tag-she-002675"],"yoast_head":"\nYantai Dongcheng Pharma Acquires Rights to 18F-APN-1607 from Aprinoia Therapeutics - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) announced the plan to acquire the clinical trial approval and research and development (R&D) materials of 18F-APN-1607, a Tau protein positron photography tracer used for PET imaging diagnosis, from Japan\u2019s Aprinoia Therapeutics Inc. and Aprinoia Therapeutics Suzhou, along with exclusive clinical development, manufacturing, and marketing rights in mainland China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=23749\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Yantai Dongcheng Pharma Acquires Rights to 18F-APN-1607 from Aprinoia Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=23749\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-08T08:25:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-29T08:30:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23749#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23749\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Yantai Dongcheng Pharma Acquires Rights to 18F-APN-1607 from Aprinoia Therapeutics\",\"datePublished\":\"2022-12-08T08:25:00+00:00\",\"dateModified\":\"2025-01-29T08:30:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23749\"},\"wordCount\":156,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Aprinoia Therapeutics\",\"Clinical trial approval \\\/ initiation\",\"Dongcheng Pharmaceutical\",\"Finance\",\"SHE: 002675\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23749#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23749\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=23749\",\"name\":\"Yantai Dongcheng Pharma Acquires Rights to 18F-APN-1607 from Aprinoia Therapeutics - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-12-08T08:25:00+00:00\",\"dateModified\":\"2025-01-29T08:30:09+00:00\",\"description\":\"China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) announced the plan to acquire the clinical trial approval and research and development (R&D) materials of 18F-APN-1607, a Tau protein positron photography tracer used for PET imaging diagnosis, from Japan\u2019s Aprinoia Therapeutics Inc. and Aprinoia Therapeutics Suzhou, along with exclusive clinical development, manufacturing, and marketing rights in mainland China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23749#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23749\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23749#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Yantai Dongcheng Pharma Acquires Rights to 18F-APN-1607 from Aprinoia Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Yantai Dongcheng Pharma Acquires Rights to 18F-APN-1607 from Aprinoia Therapeutics - Insight, China's Pharmaceutical Industry","description":"China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) announced the plan to acquire the clinical trial approval and research and development (R&D) materials of 18F-APN-1607, a Tau protein positron photography tracer used for PET imaging diagnosis, from Japan\u2019s Aprinoia Therapeutics Inc. and Aprinoia Therapeutics Suzhou, along with exclusive clinical development, manufacturing, and marketing rights in mainland China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=23749","og_locale":"en_US","og_type":"article","og_title":"Yantai Dongcheng Pharma Acquires Rights to 18F-APN-1607 from Aprinoia Therapeutics","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=23749","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-12-08T08:25:00+00:00","article_modified_time":"2025-01-29T08:30:09+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=23749#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=23749"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Yantai Dongcheng Pharma Acquires Rights to 18F-APN-1607 from Aprinoia Therapeutics","datePublished":"2022-12-08T08:25:00+00:00","dateModified":"2025-01-29T08:30:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=23749"},"wordCount":156,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Aprinoia Therapeutics","Clinical trial approval \/ initiation","Dongcheng Pharmaceutical","Finance","SHE: 002675"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=23749#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=23749","url":"https:\/\/flcube.com\/?p=23749","name":"Yantai Dongcheng Pharma Acquires Rights to 18F-APN-1607 from Aprinoia Therapeutics - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-12-08T08:25:00+00:00","dateModified":"2025-01-29T08:30:09+00:00","description":"China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) announced the plan to acquire the clinical trial approval and research and development (R&D) materials of 18F-APN-1607, a Tau protein positron photography tracer used for PET imaging diagnosis, from Japan\u2019s Aprinoia Therapeutics Inc. and Aprinoia Therapeutics Suzhou, along with exclusive clinical development, manufacturing, and marketing rights in mainland China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=23749#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=23749"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=23749#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Yantai Dongcheng Pharma Acquires Rights to 18F-APN-1607 from Aprinoia Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23749","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23749"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23749\/revisions"}],"predecessor-version":[{"id":23751,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23749\/revisions\/23751"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23749"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23749"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23749"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}